drugset / Trial / NCT01019161
An Open Label, Single Centre Mass Balance C14 Study in Patients With Acute Myeloid Leukaemia (AML)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to assess how AZD1152 is absorbed or excreted in and out of the body in patients with Acute Myeloid Leukaemia (AML).
Timeline
- Start
- 2009-11
- Primary completion
- 2010-06
- Completion
- 2010-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | barasertib | Small molecule | 1.05 mg/ml | Intravenous |
| Subject | barasertib | Small molecule | 100 mg | Intravenous |